Clinical Trial Update: Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain [Phase 3]

View source ↗

Summary

This report notes the termination of a Phase 3 trial evaluating the fentanyl transdermal patch ZR-02-01 for moderate to severe cancer pain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Fentanyl Transdermal Patch ZR-02-01 (fentanyl)

Snippet

Sponsor: ZARS Pharma Inc. | Conditions: Pain, Cancer | Phase 3 | Status: TERMINATED